Dexcom raises outlook after Q3 results top Wall Street estimates

Dexcom (NSDQ:DXCM) raised its full-year outlook yesterday after the medical device maker topped expectations on Wall Street with its third-quarter financial results.

The San Diego, Calif.-based company posted profits of $46.6 million, or 53¢ per share, on sales of $266.7 million for the 3 months ended Sept. 30, for sales growth of 44% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were 17¢, ahead of consensus on The Street, where analysts were looking for sales of $241.3 million.

“Dexcom has maintained the strong momentum we have seen all year, with sales up 45% on a constant currency basis,” president & CEO Kevin Sayer said in prepared remarks. “Clearly, our G6 launch has been very well received and leaves us in a strong position for continued growth. We are pleased to again increase our 2018 outlook.”

Dexcom said it expects to post sales of $975 million for the full year, up from a prior forecast of $925 million.

DXCM shares closed at $132.92 apiece yesterday, up 2%.

Last month, Dexcom announced that its G6 continuous glucose monitoring system will be covered for Medicare beneficiaries. The company’s product won coverage as a therapeutic CGM system, making it available to beneficiaries who closely manage their insulin dosing.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW